EXEL

36.92

0.60% 0.22

Handel nachbörslich: 36.80 -0.12 -0.33%

Exelixis Inc (EXEL)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt EXEL? Forum Prognose

Schlusskurs vom Vortag:

$36.70

Offen:

$36.23

24-Stunden-Volumen:

3.12M

Relative Volume:

1.26

Marktkapitalisierung:

$10.31B

Einnahmen:

$2.08B

Nettoeinkommen (Verlust:

$466.92M

KGV:

23.67

EPS:

1.56

Netto-Cashflow:

$404.94M

1W Leistung:

-2.12%

1M Leistung:

-4.57%

6M Leistung:

+42.27%

1J Leistung:

+55.58%

1-Tages-Spanne:

$35.57

$37.12

1-Wochen-Bereich:

$35.57

$38.41

52-Wochen-Spanne:

$20.14

$40.02

Exelixis Inc Stock (EXEL) Company Profile

Firmenname

Exelixis Inc

Sektor

Healthcare (1164)

Branche

Biotechnology (681)

Telefon

(650) 837-7000

Adresse

1851 HARBOR BAY PARKWAY, ALAMEDA, CA

Mitarbeiter

Twitter

@exelixisinc

Nächster Verdiensttermin

2025-02-11

Neueste SEC-Einreichungen

EXEL's Discussions on Twitter

Vergleichen Sie EXEL mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
EXEL Exelixis Inc	36.92	10.31B	2.08B	466.92M	404.94M	1.56
VRTX Vertex Pharmaceuticals Inc	484.82	131.41B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	634.23	72.26B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	591.87	36.10B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	270.02	35.03B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	272.17	28.24B	3.81B	-644.79M	-669.77M	-6.24

Exelixis Inc Stock (EXEL) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-02-24	Herabstufung	Wells Fargo	Overweight → Equal Weight
2025-01-27	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2025-01-24	Herabstufung	Oppenheimer	Outperform → Perform
2024-12-20	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2024-12-17	Herabstufung	BofA Securities	Buy → Neutral
2024-10-16	Bestätigt	RBC Capital Mkts	Outperform
2024-09-19	Eingeleitet	UBS	Neutral
2024-04-11	Herabstufung	Barclays	Overweight → Equal Weight
2023-12-19	Eingeleitet	BTIG Research	Buy
2023-12-15	Eingeleitet	Citigroup	Buy
2023-09-26	Eingeleitet	H.C. Wainwright	Buy
2023-08-22	Bestätigt	Oppenheimer	Outperform
2023-08-08	Eingeleitet	SVB Securities	Market Perform
2023-07-11	Fortgesetzt	Morgan Stanley	Equal-Weight
2023-05-10	Fortgesetzt	Piper Sandler	Overweight
2023-03-09	Eingeleitet	Wells Fargo	Overweight
2023-01-26	Eingeleitet	Credit Suisse	Outperform
2022-10-18	Eingeleitet	JMP Securities	Mkt Outperform
2022-06-24	Eingeleitet	BMO Capital Markets	Outperform
2021-11-19	Eingeleitet	Piper Sandler	Overweight
2021-11-03	Fortgesetzt	Jefferies	Buy
2021-10-07	Eingeleitet	Jefferies	Buy
2021-08-06	Bestätigt	H.C. Wainwright	Buy
2021-06-15	Eingeleitet	H.C. Wainwright	Buy
2021-05-18	Fortgesetzt	Goldman	Sell
2021-03-31	Eingeleitet	Credit Suisse	Outperform
2021-03-12	Eingeleitet	Wolfe Research	Outperform
2020-03-04	Eingeleitet	Barclays	Overweight
2020-01-13	Eingeleitet	SunTrust	Buy
2019-11-13	Eingeleitet	BofA/Merrill	Buy
2019-03-18	Hochstufung	Morgan Stanley	Underweight → Equal-Weight
2018-09-17	Eingeleitet	Goldman	Neutral
2018-09-10	Eingeleitet	Morgan Stanley	Underweight
2018-05-11	Bestätigt	Needham	Buy
2017-10-17	Bestätigt	Needham	Buy
2017-10-17	Bestätigt	RBC Capital Mkts	Outperform
2017-10-16	Bestätigt	SunTrust	Buy
2017-09-22	Herabstufung	Leerink Partners	Outperform → Mkt Perform
2017-09-15	Eingeleitet	RBC Capital Mkts	Outperform
2017-09-12	Bestätigt	Needham	Buy
2017-07-14	Eingeleitet	SunTrust	Buy
2017-03-31	Eingeleitet	Needham	Buy
2017-03-16	Eingeleitet	Oppenheimer	Perform
2017-02-28	Herabstufung	Stifel	Buy → Hold
2016-11-03	Eingeleitet	Deutsche Bank	Buy
2016-10-10	Hochstufung	Piper Jaffray	Neutral → Overweight
2016-09-15	Bestätigt	Stifel	Buy

Alle ansehen

Exelixis Inc Aktie (EXEL) Neueste Nachrichten

04:41 AM

Exelixis stock holds $40 target post FDA nod By Investing.com - Investing.com South Africa

Mar 28, 2025

Mar 27, 2025

FDA Expands Exelixis Cabometyx Label For Neuroendocrine Tumors - Barchart.com

Mar 27, 2025

Exelixis’ cabozantinib approval ‘certainly positive,’ says Citi - Yahoo Finance

Mar 27, 2025

Truist Financial Reaffirms Their Buy Rating on Exelixis (EXEL) - The Globe and Mail

Mar 27, 2025

Exelixis stock holds $40 target post FDA nod - Investing.com India

Mar 27, 2025

Stifel maintains Exelixis stock hold, $36 target post FDA nod By Investing.com - Investing.com South Africa

Mar 27, 2025

Mar 26, 2025

FDA approves new treatment for advanced neuroendocrine tumors By Investing.com - Investing.com South Africa

Mar 26, 2025

Exelixis to present positive preclinical data across pipeline portfolio at AACR - Yahoo Finance

Mar 26, 2025

Leerink lifts Exelixis stock target to $33 post FDA approval By Investing.com - Investing.com Australia

Mar 26, 2025

Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold? - TradingView

Mar 26, 2025

Leerink lifts Exelixis stock target to $33 post FDA approval - Investing.com India

Mar 26, 2025

Stifel maintains Exelixis stock hold, $36 target post FDA nod - Investing.com India

Mar 26, 2025

Exelixis’ primary cancer drug wins FDA approval for neuroendocrine tumors - Endpoints News

Mar 26, 2025

FDA Approves Exelixis' Lead Cancer Drug Cabometyx For Expanded Use In Neuroendocrine Tumors - Benzinga

Mar 26, 2025

Exelixis (NasdaqGS:EXEL) Celebrates FDA Approval For Expanded CABOMETYX® Use In Treating NET - Yahoo Finance

Mar 26, 2025

Citi maintains Buy on Exelixis stock with $45 target By Investing.com - Investing.com Canada

Mar 26, 2025

Citi maintains Buy on Exelixis stock with $45 target - Investing.com India

Mar 26, 2025

Exelixis' cancer drug gets FDA approval but analysts say its priced in; shares down - TradingView

Mar 26, 2025

Exelixis wins FDA label expansion for Cabometyx (EXEL:NASDAQ) - Seeking Alpha

Mar 26, 2025

Exelixis Gets Expanded FDA Approval of Cabometyx in Advanced Neuroendocrine Tumors - MarketWatch

Mar 26, 2025

Here's Why Exelixis (EXEL) is a Strong Growth Stock - Yahoo Finance

Mar 26, 2025

Exelixis Announces U.S. FDA Approval Of CABOMETYX® (cabozantinib) For Patients With Previously Treated Advanced Neuroendocrine Tumors - MarketScreener

Mar 26, 2025

FDA approves new treatment for advanced neuroendocrine tumors - Investing.com

Mar 26, 2025

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors - Joplin Globe

Mar 26, 2025

(cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors - Business Wire

Mar 26, 2025

Proficio Capital Partners LLC Takes $706,000 Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat

Mar 26, 2025

Mar 25, 2025

Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025 - BioSpace

Mar 25, 2025

Looking Into Exelixis's Recent Short Interest - Benzinga

Mar 25, 2025

Exelixis (NASDAQ:EXEL) shareholders have earned a 16% CAGR over the last five years - simplywall.st

Mar 25, 2025

Mar 24, 2025

Biotech Leader Exelixis Eyes Buy Point In Today's Stock Market Rally - MSN

Mar 24, 2025

Mar 20, 2025

Learn to Evaluate (EXEL) using the Charts - Stock Traders Daily

Mar 20, 2025

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick - Yahoo Finance

Mar 20, 2025

Mar 19, 2025

Exelixis Growth Continues with Big Money Boosts - Yahoo Finance

Mar 19, 2025

Mar 18, 2025

Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA - Business Wire

Mar 18, 2025